Pharmaceuticals News and Research

RSS

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

Amorfix Life Sciences, a company focused on misfolded protein diseases, today reported its second quarter operating results and provided an update on the Company's diagnostic and therapeutic programs.

13 Nov 2009

CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

CNS PHARMACEUTICALS AG, (C35.F) a developer and marketer of patented natural nutraceutical products is pleased to announce that the Company’s common shares is sponsored by the German Securities Trading Bank 886 AG Wertpapier Handelsbank on the electronic trading platform Xetra.

13 Nov 2009

Global industry leaders to address key trends in bioscience industry at Biotech 2009

Biotech 2009 (www.biotech2009.org) will bring together globally-recognized industry leaders to address key trends and topics relevant to the growth and advancement of the tri-state region’s bioscience industry.

13 Nov 2009

PAF receives additional funding support for serving patients with multiple myeloma

Patient Advocate Foundation (PAF) -- a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases -- is pleased to announce that it has received additional funding support for serving patients with multiple myeloma through its Co-Pay Relief Program (CPR).

13 Nov 2009

Medicare Part D program exceeds expectations, majority of seniors approve their plan and coverage

Almost four years after the Medicare Part D prescription drug program went into effect, an overwhelming majority (88 percent) of America's seniors approve of their individual plan and coverage. In a national survey released this morning by the nonpartisan Medicare Today Coalition, 95 percent of seniors who used their plan and received prescriptions over the past year also reported that their plan has worked well, while 85 percent continue to find their monthly premium to be affordable.

13 Nov 2009

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

New and effective medicines underway for treating a wide range of diseases affecting women

Women's Health Weekly recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

13 Nov 2009

Peplin merges with LEO Pharma

Peplin, Inc. today announced that it has completed its merger with LEO Pharma A/S (LEO) after obtaining the approval of the majority of Peplin stockholders. The deal was originally announced on 3 September, 2009 when LEO, a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, agreed to acquire all outstanding securities of Peplin for approximately US$287.5 million in cash. The merger consideration will be distributed to holders of common stock and CDIs promptly.

13 Nov 2009

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Ipsen, an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

13 Nov 2009

Transcept Pharmaceuticals reports financial results for the third quarter of 2009

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience, today announced financial results for the three and nine months ended September 30, 2009.

13 Nov 2009

Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

13 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

ARYx Therapeutics announces operating results for the third quarter of 2009

ARYx Therapeutics, Inc. today reported results of operations and provided a general business update for the third quarter ended September 30, 2009.

12 Nov 2009

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Senesco Technologies, Inc. announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference.

12 Nov 2009

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).

12 Nov 2009

Pharmos announces financial results for the third quarter of 2009

Pharmos Corporation today reported financial results for the third quarter and nine-month period ended September 30, 2009.

12 Nov 2009

Biostar Pharmaceuticals reports financial results for the third quarter of 2009

Biostar Pharmaceuticals, Inc., a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced financial results the third quarter ended September 30, 2009.

12 Nov 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.

12 Nov 2009

Pharmaceuticals News and Research

Amorfix Life Sciences reports operating results for the three months ended September 30, 2009

CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

Global industry leaders to address key trends in bioscience industry at Biotech 2009

PAF receives additional funding support for serving patients with multiple myeloma

Medicare Part D program exceeds expectations, majority of seniors approve their plan and coverage

Shire announces findings from Phase 3 study data with Vyvanse

New and effective medicines underway for treating a wide range of diseases affecting women

Peplin merges with LEO Pharma

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Transcept Pharmaceuticals reports financial results for the third quarter of 2009

Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

ARYx Therapeutics announces operating results for the third quarter of 2009

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Cequent Pharmaceuticals proposes the first test of an orally administered RNA interference drug in humans

Pharmos announces financial results for the third quarter of 2009

Biostar Pharmaceuticals reports financial results for the third quarter of 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring